Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

KLRA stock hub

Kailera Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

KLRAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

2.8B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

KLRA

In the news

Latest news · KLRA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-36.9

P25 -105.6P50 -46.5P75 -3.1

ROIC-24.2

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All KLRA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

125

Groups with data

Currency

USD

Showing 125 of 125 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0002096997
Company name	Kailera Therapeutics, Inc.
Country	United States
Country code	US
Cusip	482931102
Employees	145
Enterprise value	$2.1B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2026-04-17
Isin	US4829311020
Last refreshed	2026-05-10
Market cap	$2.8B
Market cap category	Mid-Cap
Price	$21.47
Sector	Healthcare
Sic	2834
Symbol	KLRA
Tags	pharmaceuticals
Website	https://www.kailera.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-5.36%
FCF yield	-4.4%
P/B ratio	4.37x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-149M
Net Income Growth Years	0%
Profit Per Employee	$-1M
ROA	-22.73
ROCE	-24.52
ROE	-36.9
ROIC	-24.18

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$692.3M
Cash	$546.1M
Current Assets	$557.5M
Current Liabilities	$46.4M
Debt	$10.8M
Debt Equity	$0.02
Equity	$635.9M
Liabilities	$56.4M
Long Term Assets	$134.8M
Long Term Liabilities	$10M
Net Cash	$642M
Net Cash By Market Cap	$23.08
Net Debt Equity	$-1.01
Tangible Book Value	$-356.5M
Tangible Book Value Per Share	$-18,714

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	12.01
Net Working Capital	$-33.9M
Quick ratio	11.83
Working Capital	$511.1M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
All Time High	28.23
All Time High Change	-23.94%
All Time High Date	2026-04-20
All Time Low	20.87
All Time Low Change	2.9%
All Time Low Date	2026-04-27
ATR	2.24
Beta1y	70.82
High	24.27
High52	28.23
High52 Date	2026-04-20
High52ch	-23.94%
Low	21.22
Low52	20.87
Low52 Date	2026-04-27
Low52ch	2.9%
RSI	27.99
RSI Monthly	0
RSI Weekly	0
Sharpe ratio	-4.17x
Sortino ratio	-4.42
Tr1w	-14.63%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$-158.3M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	58,909,792%
Float Percent	45.48%
Net Borrowing	100,000,000
Shares Institutions	7.47%
Shares Out	129,537,314

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-133.2M
Average Volume	1,377,053.63x
Bv Per Share	-18,713.7
CAPEX	$-2.1M
Ch1w	-14.63
Change	-4.45%
Change From Open	-4.66
Close	22.47
Days Gap	0.22
Depreciation Amortization	310,000
Dollar Volume	9,578,325.2
Earnings Date	2026-05-23
Earnings Time	amc
EBIT	$-158.3M
EBITDA	$-158M
EPS	$-7,820
F Score	1
FCF	$-122.3M
FCF EV Yield	-5.72x
FCF Per Share	$-0.94
Financing CF	598,659,000
Fiscal Year End	December
Founded	2,024
Investing CF	-492,599,000
Ipr	34.19
Iprfo	-17.42
Is Primary Listing	1
Is Spac	No
Last Split Type	Never
Net CF	-14,150,000
Next Earnings Date	2026-05-23
Open	22.52
Optionable	No
Position In Range	8.2
Post Close	21.47
Postmarket Change Percent	2.89
Postmarket Price	$22.09
Ppne	12,418,000
Price Date	2026-05-08
Relative Volume	0.32x
Share Based Comp	10,940,000
Us State	Massachusetts
Volume	446,126

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does KLRA pay a dividend?

Capital-return profile for this ticker.

Ownership

Who owns KLRA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+7.5%

Float: +45.5% of shares outstanding

Insider ownership

n/a

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

n/a

Negative means the company is buying back shares.

Technical

KLRA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

28.0

Below 30: short-term oversold

Price vs 200-day MA

n/a

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

-4.17

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About KLRA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current KLRA stock rating?

Kailera Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full KLRA analysis?

The full report lives at /stocks/KLRA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for KLRA?

The latest report frames KLRA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the KLRA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.